Cyclobenzaprine hydrochloride very low dose - Tonix Pharmaceuticals

Drug Profile

Cyclobenzaprine hydrochloride very low dose - Tonix Pharmaceuticals

Alternative Names: cyclobenzaprine HCL; KRL-102; TNX-102; TNX-102 SL; Tonmya; VLD-cyclobenzaprine

Latest Information Update: 17 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vela Pharmaceuticals
  • Developer Tonix Pharmaceuticals Holding Corp
  • Class Anxiolytics; Dibenzocycloheptenes; Muscle relaxants; Small molecules
  • Mechanism of Action Alpha 1 adrenergic receptor antagonists; Histamine H1 receptor antagonists; Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Post-traumatic stress disorders
  • Preclinical Agitation
  • Discontinued Fibromyalgia

Most Recent Events

  • 21 Aug 2018 Retrospective data from the phase III HONOR trial in Post-traumatic stress disorder released by Tonix Pharmaceuticals
  • 27 Jul 2018 Tonix Pharmaceuticals terminates the phase III trial in Post-traumatic stress disorder in USA due to due to inadequate separation on primary efficacy endpoint in the lead-in HONOR study (NCT03110575)
  • 27 Jul 2018 Interim efficacy and adverse events data from the phase III HONOR trial in Post-traumatic stress disorder released by Tonix Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top